Adlai Nortye Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANL Nasdaq 2836 www.adlainortye.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adlai Nortye Ltd.

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - Feb 12th, 2026 2:00 am
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing - Feb 3rd, 2026 5:00 am
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair - Jan 30th, 2026 7:14 am
Investors Calmed by Trump's Choice of Warsh as Fed Chair, Look Ahead to Inflation Data - Jan 30th, 2026 5:59 am
Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last week - Jan 28th, 2026 4:22 am
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - Dec 29th, 2025 4:00 am
Adlai Nortye to Participate in Upcoming Investor Conferences - Nov 21st, 2025 6:00 am
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 21st, 2025 10:00 pm
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 13th, 2025 9:07 pm
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025 - Apr 10th, 2025 6:00 am